Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) EBT (2016 - 2025)

Karyopharm Therapeutics' EBT history spans 14 years, with the latest figure at $90.1 million for Q4 2025.

  • For Q4 2025, EBT rose 390.99% year-over-year to $90.1 million; the TTM value through Dec 2025 reached -$3.6 million, up 95.27%, while the annual FY2025 figure was -$3.6 million, 95.27% up from the prior year.
  • EBT reached $90.1 million in Q4 2025 per KPTI's latest filing, up from -$33.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $101.3 million in Q4 2023 to a low of -$57.3 million in Q1 2021.
  • Average EBT over 5 years is -$16.9 million, with a median of -$34.3 million recorded in 2023.
  • Peak YoY movement for EBT: skyrocketed 1194.74% in 2021, then tumbled 255.97% in 2025.
  • A 5-year view of EBT shows it stood at $68.7 million in 2021, then crashed by 155.98% to -$38.4 million in 2022, then skyrocketed by 363.62% to $101.3 million in 2023, then tumbled by 130.57% to -$31.0 million in 2024, then soared by 390.99% to $90.1 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's EBT are $90.1 million (Q4 2025), -$33.1 million (Q3 2025), and -$37.2 million (Q2 2025).